Latin America Infectious Disease Immunoassay Testing Market - Size, Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Latin America Infectious Disease Immunoassay Testing Market Overview

The Latin America infectious disease immunoassay testing market reached a value of approximately USD 1.30 Billion in 2025. The market is experiencing steady growth, supported by increasing infectious disease prevalence, expanding laboratory capabilities, and greater adoption of advanced diagnostic technologies. Immunoassay testing is widely utilized for the detection of viral, bacterial, fungal, and parasitic infections, enabling timely diagnosis and effective disease management. Government-led surveillance initiatives, healthcare infrastructure improvements, and rising investments in diagnostic modernization continue supporting market expansion. Ongoing technological advancements, growing awareness of early disease detection, and increasing access to automated immunoassay platforms are further strengthening the market across Latin America.

Latin America Infectious Disease Immunoassay Testing Market Growth Analysis and Key Influencers

Latin America Infectious Disease Immunoassay Testing Market Dynamics

This section analyzes factors influencing the market, including infectious disease prevalence, laboratory modernization, diagnostic technology advancements, regulatory frameworks, healthcare investments, public health initiatives, reimbursement policies, and expanding access to immunoassay testing services.

Latin America Infectious Disease Immunoassay Testing Market Growth Drivers

Rising Automation Investments Accelerating Infectious Disease Diagnostic Market Growth Globally

Growing laboratory automation, increasing infectious disease surveillance, and stronger healthcare investments are expected to expand diagnostic capacity throughout the forecast period. For instance, in March 2026, Roche introduced the CE-marked cobas MPX-E assay, a single high-throughput test detecting HIV, HBV, HCV, and HEV simultaneously for blood donor screening. The assay improves workflow efficiency while reducing turnaround time, strengthening adoption of Chemiluminescent Immunoassay (CLIA) solutions in modern diagnostic laboratories.

Latin America Infectious Disease Immunoassay Testing Market Restraints

Evolving Regulatory Standards Creating Compliance Challenges for Global Diagnostic Manufacturers

Increasing innovation and expanding infectious disease testing continue supporting market expansion; however, stricter regulatory expectations are expected to influence commercialization during the forecast period. For instance, in April 2026, Roche received FDA 510(k) clearance for its Elecsys Anti-HBc IgM assay, demonstrating the extensive validation required before introducing new infectious disease immunoassays. Such regulatory processes may extend product development timelines while ensuring testing quality, affecting laboratory testing implementation worldwide.

Latin America Infectious Disease Immunoassay Testing Market Opportunities

Next-Generation Blood Screening Solutions Expanding Future Diagnostic Market Opportunities Worldwide

Growing demand for comprehensive infectious disease screening, improved blood safety, and advanced laboratory efficiency is expected to create substantial market opportunities. For instance, in July 2026, Roche received CE Mark for its Elecsys IGRA TB blood test, providing automated tuberculosis infection detection on cobas immunoassay systems with significantly faster processing. The launch expands laboratory testing capabilities and creates broader opportunities for Diagnostics across global healthcare systems.

Latin America Infectious Disease Immunoassay Testing Market Trends

High-Throughput Multiplex Assays Reshaping Infectious Disease Testing Market Development Globally

Increasing laboratory consolidation, growing automation, and rising demand for multi-target infectious disease detection are expected to influence future market development. For instance, in June 2026, Abbott obtained FDA approval for the HIV Combo Next Assay on the Alinity i platform, enabling simultaneous qualitative detection of HIV antigen and antibodies through a single chemiluminescent assay. This reflects the growing trend toward multiplex immunoassay technologies supporting efficient infectious disease testing.

Latin America Infectious Disease Immunoassay Testing Market Share

Blood, Serum, and Plasma Likely to Dominate the Market Segment by Sample Type

Blood-derived specimens remain the preferred sample category because they support broad infectious disease detection and compatibility with established immunoassay platforms. Their routine use strengthens diagnostic efficiency and clinical reliability across healthcare facilities. Blood, serum, and plasma held about 71% market share in the historical period and are likely to dominate the market during the forecast period, supported by widespread clinical utilization and standardized laboratory practices.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Latin America Infectious Disease Immunoassay Testing Market Analysis by Region

Brazil remains a major contributor to the regional diagnostics landscape because of its large healthcare network, expanding laboratory infrastructure, and sustained investments in infectious disease surveillance. Continued modernization strengthens market development across the country. Brazil held about 39% market share in the historical period and is likely to dominate the market during the forecast period, supported by healthcare expansion, diagnostic innovation, and public health initiatives.

Leading Players in the Latin America Infectious Disease Immunoassay Testing Market

Latin America Infectious Disease Immunoassay Testing Market Segmentation

Key Questions Answered in the Latin America Infectious Disease Immunoassay Testing Market Report

• What was the Latin America infectious disease immunoassay testing market value in 2025?
• What is the Latin America infectious disease immunoassay testing market forecast outlook for 2026-2035?
• What major factors aid the demand for the Latin America infectious disease immunoassay testing market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Latin America infectious disease immunoassay testing market trends?
• Which product and service segment is expected to dominate the market?
• Which type of testing segment is expected to hold the largest market share?
• Which sample type is expected to account for the highest market share?
• Which disease type is expected to account for the highest market share?
• Which technology is expected to account for the highest market share?
• Which application is expected to account for the highest market share?
• Which end user is expected to account for the highest market share?
• Who are the key players in the Latin America infectious disease immunoassay testing market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with diagnostic manufacturers, laboratory managers, microbiologists, clinicians, regulatory specialists, and professionals involved in infectious disease immunoassay testing across Latin America.
• Secondary Research: Sources included company announcements, CE-marking updates, technical documents, MedTech Latin America publications, regulatory reports, scientific journals, and peer-reviewed studies on testing.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops.